Endothelial contribution to blood-clotting in myeloproliferative neoplasms
Official title: Engineered microsystems to assess endothelial contribution to myeloproliferative neoplasm thrombosis
Funded at University of Minnesota · NIH-11392884 · Data updated 2026-11-12
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $171,180 |
| NIH project number | 5K08HL159289-05 |
| Project ID | NIH-11392884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with myeloproliferative neoplasms, especially those with or at risk for thrombosis.
✕Less likely to help
Healthy individuals or MPN patients not at risk for thrombosis may not directly benefit.
What this research studies
Researchers at the University of Minnesota will study how endothelial cells interact with abnormal blood cells in MPNs to cause clots. They will use patient-derived blood vessel cells and lab models to look at inflammatory and clotting signals, and test medications that block JAK signaling to see if clotting can be reduced. The goal is to pinpoint how vascular cells contribute to thrombosis so future therapies can prevent life-threatening events. The work combines patient samples and experimental models to better understand a key driver of MPN complications.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to prevent dangerous blood clots in MPN patients.
How similar studies have gone: Preclinical studies have shown endothelial involvement and JAK-STAT signaling links to clotting in MPNs, supporting potential relevance of this approach.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Beckman, Joan Denise — University of Minnesota
- Study coordinator: Beckman, Joan Denise
Related research
Other NIH-funded projects on the same topics.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Understanding blood clotting mechanisms in certain blood cancers
This study is looking into how blood clots form in people with myeloproliferative neoplasms (a type of blood cancer) to find new ways to help prevent serious complications, and it’s designed for patients who want to learn more about their condition and potential treatments.
-
Understanding how blood vessel cells contribute to blood clots in certain blood cancers
This study is looking at how certain cells in your blood vessels might contribute to blood clots in people with myeloproliferative neoplasms (MPNs), especially those with a specific mutation, and it aims to understand how current medications can help, with the possibility of you providing blood samples to assist in thi
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.